#1 Clinical Trials Search in Europe

Mps-215

This article summarizes several clinical trials investigating the use of MPS-215, a component of the cancer vaccine TEDOPI (OSE2101), for treating various advanced cancers including non-small cell lung cancer, ovarian cancer, and pancreatic cancer. TEDOPI contains multiple peptides including MPS-215 and is being studied alone and in combination with other therapies as a potential immunotherapy treatment option for patients with advanced cancers.

Table of Contents

What is MPS-215?

MPS-215 is one of the key components of TEDOPI, an innovative cancer vaccine being developed by OSE Immunotherapeutics[1]. TEDOPI, also known as OSE2101, EP2101, or IDM2101, is a combination of 10 synthetically manufactured peptides, including MPS-215[2]. This vaccine is designed to stimulate the immune system to fight against certain types of cancer.

How Does MPS-215 Work?

As part of the TEDOPI vaccine, MPS-215 works by activating the body’s immune system to recognize and attack cancer cells. The vaccine is specifically designed for patients with a particular genetic profile called HLA-A2 positive[1]. This means that the vaccine is tailored to work with the patient’s own immune system, potentially making it more effective than traditional treatments for some patients.

What Conditions Does MPS-215 Treat?

MPS-215, as part of the TEDOPI vaccine, is being studied for the treatment of several types of cancer, including:

  • Non-Small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all lung cancers[1].
  • Ovarian Cancer: Specifically, it’s being studied for platinum-sensitive recurrent ovarian cancer[3].
  • Pancreatic Cancer: The vaccine is being tested in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma[4].

Clinical Trials Involving MPS-215

Several clinical trials are currently underway to evaluate the effectiveness of TEDOPI, which includes MPS-215:

  • ARTEMIA Study: This is a phase 3 trial comparing TEDOPI to docetaxel in patients with advanced non-small cell lung cancer who have developed resistance to immune checkpoint inhibitors[1].
  • TEDOVA Study: This phase 2 trial is evaluating TEDOPI alone or in combination with pembrolizumab as a maintenance treatment for patients with platinum-sensitive recurrent ovarian cancer[3].
  • TEDOPAM Study: This phase 2 study is looking at TEDOPI plus FOLFIRI chemotherapy as a maintenance therapy for patients with advanced pancreatic cancer[4].

How is MPS-215 Administered?

MPS-215, as part of the TEDOPI vaccine, is administered as a subcutaneous injection (an injection under the skin)[1]. The exact dosing schedule may vary depending on the specific clinical trial and the condition being treated. In some studies, patients receive up to 13 injections over a period of about two years[4].

Potential Side Effects

As with any medical treatment, there may be potential side effects associated with TEDOPI, including MPS-215. While specific side effects for MPS-215 alone are not detailed in the provided information, cancer vaccines in general may cause:

  • Injection site reactions (redness, swelling, or pain at the injection site)
  • Flu-like symptoms (fever, chills, fatigue)
  • Muscle or joint pain
  • Nausea
  • Headache

It’s important to note that the safety profile of TEDOPI is still being evaluated in clinical trials. Patients should discuss potential risks and benefits with their healthcare provider[3].

Conclusion

MPS-215, as a component of the TEDOPI cancer vaccine, represents a promising approach in cancer immunotherapy. By harnessing the power of the body’s own immune system, this treatment aims to provide a more targeted and potentially more effective option for certain cancer patients. While still in clinical trials, the results of these studies will help determine the future role of MPS-215 and TEDOPI in cancer treatment.

Trial Name Cancer Type Treatment Phase Primary Endpoint
ARTEMIA Metastatic NSCLC OSE2101 vs docetaxel III Overall Survival
Unnamed Advanced solid tumors or lymphomas, NSCLC OSE-279 +/- OSE2101 I/II Safety, MTD, RP2D, ORR
TEDOVA Recurrent ovarian cancer OSE2101 +/- pembrolizumab vs best supportive care II Progression-Free Survival
TEDOPAM Advanced pancreatic cancer OSE2101 + FOLFIRI vs FOLFIRI II Overall Survival at 12 months

FAQ

  • What is MPS-215? MPS-215 is one of the active substances in TEDOPI (OSE2101), an experimental cancer vaccine being studied for treating various advanced cancers. It is a synthetically manufactured peptide that is part of the multi-peptide vaccine formulation.
  • What types of cancer is MPS-215/TEDOPI being studied for? Based on the clinical trials summarized, MPS-215 as part of TEDOPI is being investigated for advanced non-small cell lung cancer (NSCLC), recurrent ovarian cancer, and locally advanced or metastatic pancreatic ductal adenocarcinoma.
  • How is TEDOPI administered? TEDOPI is administered as a subcutaneous injection or emulsion for injection, typically given every 3-6 weeks depending on the specific trial protocol.
  • What are some of the potential side effects of TEDOPI? The trials are evaluating safety, but potential side effects may include immune-related adverse events. Patients with a history of autoimmune diseases or interstitial lung disease are generally excluded from the trials as a precaution.
  • Who may be eligible to participate in these TEDOPI clinical trials? Eligibility varies by trial but generally includes adult patients with advanced cancers like NSCLC, ovarian, or pancreatic cancer who have a positive HLA-A2 phenotype. Patients must have adequate organ function and meet other specific criteria. Detailed eligibility is determined by each trial's inclusion/exclusion criteria.

Ongoing Clinical Trials on Mps-215

  • Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study on Tedopi and Nivolumab for Patients with Advanced Non-Small Cell Lung Cancer After Initial Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

    Recruiting

    3 1 1 1
    Investigated drugs:
    Belgium France Germany Greece Hungary Italy +5

  • Study of OSE-279 and OSE2101 Drug Combination for Patients with Advanced Solid Tumors, Lymphomas, or Metastatic Non-Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Spain

  • Study on Maintenance Therapy with OSE2101 and FOLFIRI for Patients with Advanced Pancreatic Cancer After Initial FOLFIRINOX Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of OSE2101 vaccine alone or with pembrolizumab as maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer after chemotherapy

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Germany

Glossary

  • TEDOPI (OSE2101): An experimental cancer vaccine containing multiple synthetic peptides including MPS-215, being studied as an immunotherapy for various advanced cancers.
  • MPS-215: One of the active substances in the TEDOPI cancer vaccine, a synthetically manufactured peptide.
  • HLA-A2 phenotype: A specific human leukocyte antigen (HLA) type that patients must have to be eligible for the TEDOPI clinical trials.
  • NSCLC: Non-small cell lung cancer, one of the cancer types being studied in the TEDOPI clinical trials.
  • Progression-Free Survival (PFS): The length of time during and after treatment that a patient lives without the disease getting worse.
  • Overall Survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Immune checkpoint inhibitor: A type of immunotherapy drug that blocks certain proteins made by immune system cells and some cancer cells, to help the immune system kill cancer cells.
  • FOLFIRINOX: A combination chemotherapy regimen used to treat pancreatic cancer, consisting of folinic acid, fluorouracil, irinotecan, and oxaliplatin.
  • Sarcopenia: Age-related loss of muscle mass and strength, being studied in relation to treatment side effects in some trials.

References

  1. http://clinicaltrials.eu/trial/study-comparing-ose2101-and-docetaxel-for-patients-with-metastatic-non-small-cell-lung-cancer-after-immunotherapy-resistance/
  2. http://clinicaltrials.eu/trial/study-of-ose-279-and-ose2101-drug-combination-for-patients-with-advanced-solid-tumors-lymphomas-or-metastatic-non-small-cell-lung-cancer/
  3. http://clinicaltrials.eu/trial/study-of-maintenance-treatments-with-ose2101-and-pembrolizumab-for-patients-with-recurrent-ovarian-cancer-after-platinum-based-chemotherapy/
  4. http://clinicaltrials.eu/trial/study-on-maintenance-therapy-with-ose2101-and-folfiri-for-patients-with-advanced-pancreatic-cancer-after-initial-folfirinox-treatment/